Drug Trial Radar · NCT00123942
Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease
Last checked: Nov 20, 2026Latest source record: Jun 14, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
31
Planned (sponsor's estimate)
Start
Apr 2004
Primary completion
Not stated
Sponsor
- Lead sponsor
- MedImmune LLCAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jul 26, 2005
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to determine the maximum tolerated dose (MTD) and safety and tolerability of MEDI-507 in patients with CD2-positive lymphoproliferative disorders.
Conditions
- Lymphoproliferative Disorders
Interventions
MEDI-507Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine the maximum tolerated dose (MTD) or the optimal biological dose
- (OBD) of MEDI-507 based on safety and tolerability of MEDI-507 in patients with
- CD-2 positive lymphoproliferative disorders.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Cancer Institute/National Institutes of Health
Bethesda, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.